Artificial intelligence and machine learning (AI/ML) are quickly becoming the norm in biopharma, with now the vast majority of drug companies implementing the technology in some way or another. Most of that has been in drug discovery and development, but it is also moving into manufacturing, marketing and regulatory functions. But as use expands, there are associated risks that companies will have to mitigate, including in areas such as data privacy, cybersecurity and intellectual property.
A report by the law firm Arnold & Porter illustrates how deeply woven into the fabric of biopharma AI/ML has become. The report, released 13 November, was based on a...
Key Takeaways
- A report by law firm Arnold & Porter found that about three-quarters of life sciences executives said they had started using AI in the last...